1119 related articles for article (PubMed ID: 12894192)
1. Biotechnology partnerships--medicine for an ailing industry?
DeLamarter J
Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
[No Abstract] [Full Text] [Related]
2. Prescription for an ailing pharmaceutical industry.
Demain AL
Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
[No Abstract] [Full Text] [Related]
3. Rediscovering plant-based drugs.
Littleton J; Falcone D; Davies HM
Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
[No Abstract] [Full Text] [Related]
4. Michigan's next wave of biopharmaceutical entrepreneurship.
Kerppola R; van de Walle M; Surine S
Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
[No Abstract] [Full Text] [Related]
5. Biotechs hold their own in shifting industry.
Mitchell P
Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
[No Abstract] [Full Text] [Related]
6. Bugs or drugs, tortoises or hares?
Jacobs T
Nat Biotechnol; 2005 Mar; 23(3):293. PubMed ID: 15765079
[No Abstract] [Full Text] [Related]
7. Earlier stage biotechs attract partners.
Ratner M
Nat Biotechnol; 2005 May; 23(5):509. PubMed ID: 15877052
[No Abstract] [Full Text] [Related]
8. Private company profiles.
Nat Biotechnol; 2003 Jul; 21 Suppl():BE23-8. PubMed ID: 12874973
[No Abstract] [Full Text] [Related]
9. A reprise for collaborative financing in biotech.
Ransom J
Nat Biotechnol; 2006 Aug; 24(8):873-4. PubMed ID: 16900110
[No Abstract] [Full Text] [Related]
10. The quiet revolution.
Nat Biotechnol; 2003 Jul; 21(7):715. PubMed ID: 12833072
[No Abstract] [Full Text] [Related]
11. Does biotech M&A benefit investors?
Jacobs T
Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
[No Abstract] [Full Text] [Related]
12. A very firm handshake: biotech's growing negotiating power.
Thiel KA
Nat Biotechnol; 2005 Oct; 23(10):1221-6. PubMed ID: 16211058
[No Abstract] [Full Text] [Related]
13. Never again.
Scott C
Nat Biotechnol; 2010 Feb; 28(2):131. PubMed ID: 20139946
[No Abstract] [Full Text] [Related]
14. Hyseq-Variagenics merger signals end of the line.
Hodgson J
Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
[No Abstract] [Full Text] [Related]
15. The 802 million dollars fallacy.
Hodgson J
Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
[No Abstract] [Full Text] [Related]
16. Advice for partnering with pharma.
Howard K
Nat Biotechnol; 2004 Nov; 22(11):1477-9. PubMed ID: 15586421
[No Abstract] [Full Text] [Related]
17. Biotech parks proliferate, despite concerns over sustainability.
Jia H; Jayaraman KS; Orellana C
Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
[No Abstract] [Full Text] [Related]
18. Value creation and sharing among universities, biotechnology and pharma.
Edwards MG; Murray F; Yu R
Nat Biotechnol; 2003 Jun; 21(6):618-24. PubMed ID: 12776145
[No Abstract] [Full Text] [Related]
19. Antiinfective biotechs face partnering gap.
Sheridan C
Nat Biotechnol; 2005 Feb; 23(2):155-6. PubMed ID: 15696131
[No Abstract] [Full Text] [Related]
20. Anthony Coyle.
Coyle A
Nat Biotechnol; 2011 Mar; 29(3):187. PubMed ID: 21390006
[No Abstract] [Full Text] [Related]
[Next] [New Search]
